Recursion Pharmaceuticals Reports 60% Revenue Decline in Q2 2026

Recursion Pharmaceuticals, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenue of $7.7 million, a 60% decrease from $19.2 million in the same period of 2025. The company's operating revenue fell to $7.3 million, down 62% year-over-year, primarily due to reduced revenue from its collaboration with Roche, which had completed certain project phases in the prior period. For the first half of 2026, total revenue was $14.1 million, compared to $34.0 million in the first half of 2025, reflecting a similar trend.

The company's net loss for the second quarter was $131.0 million, a 24% improvement from a loss of $171.9 million in the same quarter of the previous year. For the first half of 2026, the net loss was $248.5 million, down from $374.4 million in the first half of 2025. This reduction in losses was attributed to a decrease in operating costs, which fell by 27% to $142.6 million in the second quarter, driven by lower research and development expenses and general administrative costs.

Strategically, Recursion has made notable advancements in its partnerships and internal pipeline. The company has achieved $216 million in upfront and milestone payments from its collaboration with Roche and Genentech, which includes up to 40 potential small molecule discovery programs. Additionally, Recursion is progressing with its internal drug candidates, including REC-4881, a MEK1/2 inhibitor for familial adenomatous polyposis (FAP), and REC-7735, a PI3Kα H1047R inhibitor, with clinical trials expected to initiate in the second half of 2026.

As of June 30, 2026, Recursion's cash, cash equivalents, and restricted cash totaled $556.8 million, down from $753.9 million at the end of 2025. The company anticipates that its existing cash will be sufficient to fund operations for at least the next 12 months. However, it acknowledges the need for additional financing to support ongoing operations and potential product commercialization. The company has not yet generated significant revenue from product sales and continues to rely on capital raised through stock issuances and milestone payments from collaborations to fund its activities.